Quantcast
ZME Science
  • News
  • Environment
  • Health
  • Future
  • Space
  • Features
  • More
    • About
    • The Team
    • Advertise
    • Contribute
    • Our stance on climate change
    • Privacy Policy
    • Contact
No Result
View All Result
ZME Science

No Result
View All Result
ZME Science
No Result
View All Result
Home Science

Antibody blocks coronavirus infection in cultured cells

The findings lay the foundation for novel treatments that prevent the coronavirus from spreading.

Tibi Puiu by Tibi Puiu
May 4, 2020
in Science
Reading Time: 2 mins read
A A
Share on FacebookShare on TwitterSubmit to Reddit

Researchers from Europe have identified a fully human monoclonal antibody which blocks the SARS-CoV-2 virus (the one that causes COVID-19) from entering cultured cells.

The team of researchers, which are affiliated with Utrecht University, Erasmus Medical Center, and Harbour BioMed (HBM), built on previous work related to antibodies targeting SARS-CoV-1, which caused an outbreak in 2002-2003.

“Using this collection of SARS-CoV antibodies, we identified an antibody that also neutralizes infection of SARS-CoV-2 in cultured cells. Such a neutralizing antibody has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus,” said Berend-Jan Bosch, Associate Professor, Research leader at Utrecht University, and co-lead author of the new study published in Nature Communications.

The newly identified antibody binds to a domain shared by both SARS viruses, neutralizing them. Unlike antibodies derived from other organisms, the one used in the study is “fully human”, minimizing immune-related side effects.

ADVERTISEMENT

Monoclonal antibodies (mAbs) are antigen-recognizing glycoproteins that are made by identical immune cells (are clones of a unique parent cell). These antibodies are used in a number of therapies for health conditions such as autoimmune disorders, infectious diseases, and cancers.

Sorry to interrupt, but you should really...

...Join the ZME newsletter for amazing science news, features, and exclusive scoops. More than 40,000 subscribers can't be wrong.

   

This also means that treatments based on the antibody ought to be safe, although that would, of course, have to be tested in clinical trials. The fact that the therapeutic effects of the human antibody have been demonstrated only in-vitro is an important limitation that doesn’t necessarily mean it will work in-vivo.

“This is groundbreaking research,” said Dr. Jingsong Wang, Founder, Chairman & Chief Executive Officer of HBM. “Much more work is needed to assess whether this antibody can protect or reduce the severity of disease in humans. We expect to advance development of the antibody with partners. We believe our technology can contribute to addressing this most urgent public health need and we are pursuing several other research avenues.”

ADVERTISEMENT

ShareTweetShare
Tibi Puiu

Tibi Puiu

Tibi is a science journalist and co-founder of ZME Science. He writes mainly about emerging tech, physics, climate, and space. In his spare time, Tibi likes to make weird music on his computer and groom felines.

ADVERTISEMENT
ADVERTISEMENT
  • News
  • Environment
  • Health
  • Future
  • Space
  • Features
  • More

© 2007-2019 ZME Science - Not exactly rocket science. All Rights Reserved.

No Result
View All Result
  • News
  • Environment
  • Health
  • Future
  • Space
  • Features
  • More
    • About
    • The Team
    • Advertise
    • Contribute
    • Our stance on climate change
    • Privacy Policy
    • Contact

© 2007-2019 ZME Science - Not exactly rocket science. All Rights Reserved.